NCT01979380View on ClinicalTrials.gov

Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions
Drug Toxicity
Interventions
DRUG

KD101

200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning

DRUG

placebo

PO, once in the morning

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Kwang Dong Pharmaceutical co., ltd.

INDUSTRY

NCT01979380 - Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter